Berlin-based cryonics startup Tomorrow.Bio has raised a €5 million seed round to bring its futuristic vision of life extension across the Atlantic. As Europe’s first and only cryonics lab, the company now plans to launch operations in the U.S. and scale its research and development to improve preservation quality.
The funding round was co-led by Blast.Club and Truventuro, the family office of longevity-focused investor Nils Regge. It marks a significant milestone for the company, which has already cryopreserved 20 people and 10 pets and signed contracts with over 800 clients—pushing its total contract value past €160 million.
Freezing Today, Hoping for a Cure Tomorrow
Founded in 2020 by former cancer researcher Dr. Emil Kendziorra and tech entrepreneur Fernando Azevedo Pinheiro, Tomorrow.Bio offers long-term cryopreservation for individuals after legal death. Bodies are cooled to -196°C and stored in high-tech facilities in Switzerland, with the hope that future medical advances will one day make revival possible.
“Progress in curing diseases like cancer was too slow,” said Dr. Kendziorra. “Cryonics is a bet on future medicine—on a world where today’s incurable illnesses are solvable.”
A High-Tech End-of-Life Process
Tomorrow.Bio works closely with its nonprofit sister organization, the European Biostasis Foundation (EBF), based in Rafz, Switzerland. EBF houses patients in vacuum-insulated steel dewars, each 3.2 meters tall and filled with liquid nitrogen.
But cryopreservation isn’t just about storage—it’s a race against time. The company operates a fleet of specially equipped cryo-ambulances across Europe. After legal death, these “standby teams” rapidly begin the preservation process: performing chest compressions, supplying oxygen, and replacing bodily fluids with cryoprotectants to prevent tissue damage from ice crystal formation.
With the new funding, Tomorrow.Bio plans to deploy similar teams in New York, California, and Florida, becoming the first cryonics company with local rapid-response teams on both continents.
Betting Big on Longevity
For investors like Nils Regge and Blast.Club founder Anthony Bourbon, the long-term promise of cryonics isn’t just scientific—it’s a massive business opportunity.
“We’re backing moonshots with serious potential,” said Regge. “This isn’t science fiction anymore—it’s a frontier of medicine and technology.”
Tomorrow.Bio’s founders say their next phase will focus on scaling responsibly, boosting R&D, and building trust in a field often met with skepticism.
“The vision is bold, but grounded,” added Bourbon. “Tomorrow.Bio could very well redefine what it means to save a life.”
As the race to extend human life accelerates, Tomorrow.Bio is positioning itself as a frontrunner in one of the most controversial—and potentially transformative—corners of modern science.
